Lindbrook Capital’s Travere Therapeutics TVTX Stock Holding History

Lindbrook Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$20.9K	Hold	1,164	–	–	﹤0.01%	1329
2024 Q4	$20.3K	Hold	1,164	–	–	﹤0.01%	1284
2024 Q3	$16.3K	Hold	1,164	–	–	﹤0.01%	1405
2024 Q2	$9.57K	Buy	1,164 +728	+167%	+$4.9K	﹤0.01%	1650
2024 Q1	$3.36K	Buy	+436	New	+$3.68K	﹤0.01%	2062
2023 Q4	–	Sell	-99	Closed	-$885	–	2823
2023 Q3	$885	Buy	99 +62	+168%	+$875	﹤0.01%	2386
2023 Q2	$568	Buy	+37	New	+$673	﹤0.01%	2483
2022 Q4	–	Sell	-223	Closed	-$5K	–	3013
2022 Q3	$5K	Buy	+223	New	+$5.76K	﹤0.01%	1695
2021 Q4	–	Sell	-1,500	Closed	-$36K	–	2203
2021 Q3	$36K	Buy	+1,500	New	+$27.6K	0.01%	542

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lindbrook Capital's TVTX Position: Q1 2025 in Review

Lindbrook Capital held its Travere Therapeutics (TVTX) position steady in Q1 2025 at 1,164 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

Lindbrook Capital first reported a position in TVTX in Q3 2021 and has held it in 9 quarters since. The position peaked at $36K in Q3 2021. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

Lindbrook Capital held 1,164 shares of Travere Therapeutics worth $20.9K as of Q1 2025.
Lindbrook Capital left its Travere Therapeutics share count unchanged in Q1 2025.
Travere Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1329 holding.
Lindbrook Capital first reported a position in Travere Therapeutics in Q3 2021 and has held it in 9 quarters since.
Lindbrook Capital's Travere Therapeutics position peaked at $36K in Q3 2021.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.